Dihydroergocristine PDE report and OEL report profile
Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
17479-19-5
Molecular formula
C35H41N5O5
Molecular weight
611.7 g/mol
Drug class
Ergot alkaloidpartial agonist/antagonist at adrenergic, serotonergic and dopaminergic receptors
Mechanism of action
Interacts with alpha-adrenergic, serotonergic and dopaminergic receptors. The mechanism underlying historical cognitive or vascular indications is not firmly established and may vary by preparation.
Indications / reported uses
Historical or regional use in fixed ergot-alkaloid mixtures for selected vascular or cognitive symptoms; it is not an established evidence-based treatment for postpartum haemorrhage. Do not carry over that indication from RxClass.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Dihydroergocristine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Dihydroergocristine Permitted Daily Exposure (PDE) report (the Dihydroergocristine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Dihydroergocristine Occupational Exposure Limit (OEL) report (the Dihydroergocristine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.